The peptide synthesis services market is on a robust growth trajectory, driven by increasing R&D expenditure and a surge in clinical-stage peptide therapeutics. According to industry reports, the peptide synthesis market size has grown strongly in recent years, expanding from $6.18 billion in 2025 to $6.74 billion in 2026 at a CAGR of 9.1%[reference:22]. This growth is expected to accelerate, reaching $9.91 billion by 2030 at a CAGR of 10.1%[reference:23].
The customized peptide synthesis market, a key segment within this broader market, is projected to expand from approximately USD 348.2 million in 2025 to USD 489.0 million by 2032[reference:24]. This growth is fueled by the increasing demand for personalized medicine development, the rising use of peptide-based therapeutics, and the growing need for efficient drug discovery platforms[reference:25]. The global market for peptide synthesis is estimated to reach between USD 500 million and USD 1.00 billion by 2025, underscoring its pivotal role in a biopharma landscape where peptide therapeutics command annual sales surpassing USD 50 billion[reference:26].
Academic and pharmaceutical researchers are increasingly relying on specialized providers for non-GMP and GMP synthesis to accelerate drug discovery. Services such as high-throughput peptide library screening and complex conjugation—including PEGylation and fluorescent labeling—are becoming standard offerings. The market is also witnessing a surge in demand for long-chain peptides (up to 100mers) and macrocyclic peptides, which require advanced synthesis and purification technologies, driving premium pricing for specialized services.
Major trends in the forecast period include the increasing use of AI for peptide design and optimization, expansion of precision medicine applications using peptides, integration of cloud and big data for peptide research, use of IoT-enabled laboratory devices for real-time monitoring, and implementation of smart manufacturing in peptide production[reference:27]. Companies are also concentrating on developing next-generation peptide synthesizers to strengthen their competitive position[reference:28]. For example, Vapourtec Ltd launched the Peptide-Builder in August 2025, a compact benchtop peptide synthesizer incorporating continuous-flow solid-phase peptide synthesis technology[reference:29].
The rising incidence of chronic diseases is a significant driver of growth in the peptide synthesis market[reference:30]. Noncommunicable diseases remain the leading cause of death and disability worldwide, with 1 in 5 men and 1 in 10 women dying before age 70 due to conditions such as cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes[reference:31]. Peptide synthesis plays an important role in addressing these chronic diseases, as certain peptides exhibit anti-inflammatory and antioxidant properties that can support the prevention and management of various conditions[reference:32].